Results 91 to 100 of about 824,117 (206)

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]

, 2010
Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Sayyed, Sufyan Ali, Anders, Hans-Joachim, Vielhauer, Volker   +2 more
core   +1 more source

Analysing the Combined Effects of Radiotherapy and Chemokine Receptor 5 Antagonism: Complementary Approaches to Promote T Cell Function and Migration in Oesophageal Adenocarcinoma

Biomedicines
The presence of an immunosuppressive tumour microenvironment in oesophageal adenocarcinoma (OAC) is a major contributor to poor responses. Novel treatment strategies are required to supplement current regimens and improve patient survival.
Maria Davern, Cillian O’ Donovan, Noel E. Donlon, Eimear Mylod, Caoimhe Gaughan, Anshul Bhardwaj, Andrew D. Sheppard, Dara Bracken-Clarke, Christine Butler, Narayanasamy Ravi, Claire L. Donohoe, John V. Reynolds, Joanne Lysaght, Melissa J. Conroy   +13 more
doaj   +1 more source

Maraviroc attenuates trauma-hemorrhage-induced hepatic injury through PPAR gamma-dependent pathway in rats.

PLoS ONE, 2013
Maraviroc is a CC-chemokine receptor 5 (CCR5) antagonist with potent antiviral and cancer preventive effects. Recent evidence suggests that the co-existence of CCR5 in various cell types is involved in inflammation.
Fu-Chao Liu, Yung-Fong Tsai, Huang-Ping Yu   +2 more
doaj   +1 more source

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

Allergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti, Chiara Vasco, Francesca Clemente, Paola Larghi, Sara Maioli, Edoardo Scarpa, Elena Carelli, Nadia Pulvirenti, Maria Lucia Sarnicola, Mariacristina Crosti, Manal Bel Imam, Willem van de Veen, Loris Rizzello, Sergio Abrignani, Lucia A. Baselli, Rosa Maria Dellepiane, Maria Carrabba, Giovanna Fabio, Jens Geginat   +18 more
wiley   +1 more source

Total Synthesis of Anibamine, a Novel Natural Product as a Chemokine Receptor CCR5 Antagonist

, 2016
The total synthesis of anibamine, the first and only natural product known as a chemokine receptor CCR5 antagonist, is reported herein.
Guo Li (174860), Yan Zhang (8098), Robert W. Buckheit (840079), Karen Watson (2493043)   +3 more
core   +1 more source

Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents

eLife
C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use.
Ayni Sharif, Matthew S Jeffers, Dean A Fergusson, Raj Bapuji, Stuart G Nicholls, John Humphrey, Warren Johnston, Ed Mitchell, Mary-Ann Speirs, Laura Stronghill, Michele Vuckovic, Susan Wulf, Risa Shorr, Dar Dowlatshahi, Dale Corbett, Manoj M Lalu   +15 more
doaj   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist

, 2016
This report describes the discovery of a potent, orally bioavailable CC chemokine receptor 2 (CCR2) antagonist which, while optimized for CCR2 potency, also had potent CC chemokine receptor 5 (CCR5 ...
Mary Struthers (1416985), Alexander Pasternak (161010), Jerry Di Salvo (1417030), Lihu Yang (1570837), Ruth Kilburn (2307298), Thomas Wisniewski (167506), Pasquale P. Vicario (2307301), Sander G. Mills (2085178), Julie A. DeMartino (2093296), Stephen D. Goble (1417033), Julia M. Ayala (2307295)   +10 more
core   +1 more source

CCR5 Utilization of Transmitted and Early Founder HIV-1 Envelopes and the Sensitivity to Small CCR5 Inhibitors [PDF]

, 2008
Huang, X, Hu, Q, Shattock, RJ
core   +3 more sources